“If you already have zero enterprise apps in Python, that remains the right number and Gen AI should not change that at all.” Rod Johnson, October, 2025.
Garbage Chairs of Amsterdam.
Reducing the 7 R's of modernization down to 3 - new take on tech debt, from Charles Betz
Where once there were 7, now there are three:
Forrester data provides clear guidance on where organizations should focus. Knowledge and process debt, selected by 37% of respondents, demands immediate attention through process improvement, reengineering, and organizational change management. Unsupported vendor software and redundant IT systems, each selected by 30–32% of respondents, require proactive migration planning before crisis points emerge. System inflexibility, identified by 35%, calls for architectural investments that preserve future options.
My daughter’s swim school has a (brown) bar connected to it that has panoramic windows looking into the pool. It’s not number one, but this is very high up on the list of “Most Dutch Thing Ever.”
Only three kinds of AI products actually work - “For my money, the current multi-billion-dollar question is can AI agents be useful for tasks other than coding?” // Good thinking about productizing AI: what seems to work and not work.
AI, banks, mainframes, and on-premises
Above related to spending on EU sovereign cloud for AI, the lack of AI app explosion in the enterprise (see the product management/design take), and pondering why banks don’t run 100% of their IT in the public cloud.
“Nobody below colonoscopy age remembers the expectation of paying for a news story to read the whole thing.” How Elon Musk’s Changes to X Made Our Discourse Far Stupider
I’m no epidemiologist, but all of this seems like the biggest positive health impact since vaccines. In the America, all my life The System and The Culture have been telling us we’re overweight and that is causes problems. No doubt, a lot of healthcare spend is in response to that.
Well. This seems like a legit “quick fix.”
If generic semaglutide were made available to everyone with obesity and diabetes globally, it could save 2.1m-3.1m lives a year, according to one model. Moreover, glp-1 medications are known to reduce cardiovascular events, improve sleep apnoea, protect the kidneys and liver, and even show promise for reducing addictive behaviours. Early data have even hinted at reduced risks of cancer and Alzheimer’s. More results on these unexpected side-benefits of GLP-1 use will be published in the coming months. However you slice it, 2026 is shaping up to be a pivotal year for these remarkable drugs.
It feels like these drugs, popular as they are, are likely “under-rated” in that they would address huge, systemic problems in US health. Hopefully it will and they’ll become “boring” like vaccines and high blood pressure medicine.
He goes hard and detailed in the Masto recco.